Viking Therapeutics Inc. has detailed its latest advancements in the development of novel therapeutics for metabolic and endocrine diseases. The company highlighted its clinical programs, including VK2735, a dual GLP-1/GIP agonist for obesity, which successfully achieved its primary endpoint in the VENTURE Phase 2 obesity study, with a Phase 3 study planned for the second quarter of 2025. Additionally, the VK2735 oral version has completed Phase 2 enrollment after demonstrating positive proof of concept and weight reduction in Phase 1. For NASH/MASH, VK2809, a selective thyroid receptor-β agonist, successfully completed the VOYAGE Phase 2b trial, meeting primary and secondary endpoints. In the rare disease domain, VK0214, another thyroid receptor-β agonist, showed proof of concept in reducing key biomarkers in X-ALD patients during Phase 1b studies. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。